Zevra Therapeutics, Inc. ZVRA
11.04
(0.22)
(1.95%)
as of 25 Sep
- Market cap
- $668.7M
- P/E
- 11.6×
Follow ZVRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.09 | 4.55 | 6.54 | 19.02 |
+8 more quarters Free account |
P/S ratio |
6.23 | 4.45 | 4.65 | 6.31 | |
P/FCF ratio |
25.65 | 43.60 | 0.00 | 0.00 | |
P/Operating CF |
49.81 | 88.63 | 89.85 | 113.00 | |
P/B ratio |
3.90 | 2.65 | 3.20 | 4.00 | |
Price to Tangible BV |
4.09 | 2.79 | 3.45 | 4.37 | |
EV/Sales |
5.34 | 3.63 | 3.80 | 5.11 | |
EV/EBITDA |
9.01 | 8.43 | 0.00 | 0.00 | |
EV/Operating CF |
21.75 | 34.73 | (252.94) | (18.47) | |
EV/FCF |
21.96 | 35.51 | (203.63) | (18.20) | |
Quick Ratio |
5.02 | 4.74 | 5.46 | 8.29 | |
Current Ratio |
5.17 | 4.89 | 5.68 | 8.62 | |
Net Debt/EBITDA |
(13.39) | (3.87) | (14.64) | (41.58) | |
Debt/Assets |
0.00% | 0.00% | 21.75% | 22.70% | |
Debt/Equity |
0.00 | 0.00 | 0.40 | 0.46 | |
Asset Turnover |
0.49 | 0.54 | 0.46 | 0.37 | |
Operating CF/Net income |
2.03 | 0.17 | 0.41 | (8.66) | |
Capex/Depreciation |
(20.52) | (171.65) | 0.22 | (0.04) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.31% | 12.13% | 7.68% | 13.17% | |
Selling, General and Administrative Expense of Revenue |
41.75% | 57.38% | 59.65% | 64.98% | |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
7.49% | 8.57% | 12.55% | 10.63% | |
Graham Net Nets |
0.20 | 0.29 | 0.19 | 0.17 | |
Graham Number |
8.87 | 12.75 | 9.28 | 5.17 | |
Earnings Yield |
6.62% | 22.00% | 15.29% | 5.26% | |
Free Cash Flow Yield |
3.90% | 2.29% | (0.40%) | (4.46%) | |
Revenue per Share |
0.67 | 0.62 | 0.62 | 0.47 | |
Operating CF per Share |
0.29 | 0.11 | 0.10 | 0.08 | |
Capex per Share |
0.08 | 0.75 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.37 | 0.86 | 0.10 | 0.08 | |
Cash per Share |
3.75 | 3.43 | 3.45 | 3.57 | |
Shareholders Equity per Share |
3.68 | 3.52 | 2.80 | 2.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.68 | 3.52 | 2.80 | 2.38 | |
Free Cash Flow |
21.77 | 50.08 | 5.41 | 4.74 | |
Working Capital |
202.67 | 182.94 | 183.73 | 199.00 | |
Capital Expenditures |
4.74 | 43.94 | (0.11) | 0.04 | |
Net Current Asset Value |
166.24 | 157.19 | 92.93 | 88.16 | |
EV/EBIT |
8.82 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.12) | (1.21) | 0.00 | 0.00 | |
Net Profit Margin |
21.16% | 100.27% | 39.03% | (2.09%) | |
Price to Operating Income |
10.30 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.38 | 17.36 | 16.88 | 12.32 | |
Average Payables |
14.90 | 14.75 | 18.53 | 17.77 | |
Average Inventory |
1.78 | 2.43 | 1.86 | — | |
Average Assets |
279.49 | 225.64 | 231.43 | 230.83 | |
Average Common Equity |
167.44 | 123.41 | 97.16 | 101.47 |
Columns are period end dates